Suchergebnisse - "Rini, Brian I"

PubPharm (637)

1

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2024

von Carril-Ajuria, L. | Lavaud, P. | Dalban, C. | +19

2

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

enthalten in: Cancer cell | 2024

von Saliby, R. | Labaki, C. | Jammihal, T. | +21

3

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

enthalten in: Investigational new drugs | 2024

von Beckermann, K. | Patnaik, A. | Winer, I. | +6

4

PADRES : a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy

enthalten in: BJU international | 2024

von Hakimi, K. | Campbell, S. | Nguyen, M. | +7

5

Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib : Analysis of the Phase III TIVO-3 Trial

enthalten in: The oncologist | 2024

von Beckermann, K. | Asnis-Alibozek, A. | Atkins, M. | +8

6

Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma

enthalten in: Cancer discovery | 2024

von Choueiri, T. | Donahue, A. | Braun, D. | +10

7

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Chang, E. | Zhou, J. | Song, C. | +15

8

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

enthalten in: Investigational new drugs | 2024

von Beckermann, K. | Patnaik, A. | Winer, I. | +6

9

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma : 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454

enthalten in: European urology | 2024

von Plimack, E. | Powles, T. | Stus, V. | +18

ErratumFor: Eur Urol. 2023 Nov;84(5):449-454. - PMID 37500340

10

LITESPARK-012 : pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma

enthalten in: Future oncology (London, England) | 2023

von Choueiri, T. | Powles, T. | Voss, M. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[64]